Drug Database
Back to search

Poland· PL-100445816

REKAMBYS

A rilpivirine product containing rilpivirinum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.

ATC J05AG05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedREKAMBYSATCJ05AG05REGISTER NO.PL-100445816PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rilpivirinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rilpivirine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AG05 (rilpivirine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search rilpivirine products by name

Rilpivirine · ATC J05AG05

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rilpivirine costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $6.77 in France to $13.46 in Switzerland — a ×2.0 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Rilpivirine · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$13.46
  • FR France$6.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Rilpivirinum
Manufacturer
Janssen-Cilag International N.V.
Country
Poland (PL)
ATC code
J05AG05
ATC class
Rilpivirine
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    08470007300441
  • gtin
    05413868120042

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

239 interactions on record for rilpivirine.

Graded by severity as the source publishes them — 58 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rilpivirine against other medicinesHow interaction checks work

Rilpivirine · interactions on record

239 records

  • 58 severe
  • 179 moderate
  • 2 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • NizatidineA02BA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rilpivirine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rilpivirine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Edurant, Rekambys
  • Liechtenstein · Edurant, Rekambys
  • Norway · Edurant, Rekambys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9a75135a-89d2-449a-b9ac-0ab6d0f4988f
GET /v1/drugs/9a75135a-89d2-449a-b9ac-0ab6d0f4988f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Zawiesina do wstrzykiwań o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "900 mg",
  "packaging": "05413868120042 ¦ Rpz ¦ EU/1/20/1482/002 ¦ 138793\n1 fiol. 4 ml ¦ 1 igła  + 1 adapter fiolki ¦ 1 strzyk. \n¦ UR/Z/4c/090/22 - 08470007300441",
  "substance": "Rilpivirinum 900 mg",
  "common_name": "Rilpivirinum",
  "pl_product_id": "100445816",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about rilpivirine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console